Online citations, reference lists, and bibliographies.
← Back to Search

Self-Reported Initial Management Of Childhood Idiopathic Thrombocytopenic Purpura: Results Of A Survey Of Members Of The American Society Of Pediatric Hematology/Oncology, 2001

S. Vesely, G. Buchanan, L. Adix, J. George, A. Cohen, V. Blanchette, T. Kühne
Published 2003 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The purpose of this study was to update physicians' self-reported initial management practices for childhood idiopathic thrombocytopenic purpura (ITP) from an initial survey in 1997. A questionnaire was sent by e-mail in October 2001 to 753 members of the American Society of Pediatric Hematology/Oncology (ASPH/O). The questionnaire had 14 questions, based on the clinical presentation of a 5-year-old boy with ITP, a platelet count of 7,000/&mgr;L, scattered petechiae, and no mucous membrane bleeding. Two hundred eighteen (29%) surveys were returned. In response to questions regarding initial treatment, 33% of physicians said they would always administer drug therapy, 38% usually, 15% sometimes, and 14% rarely/never. When asked which agent would be used if drug treatment were prescribed, 45% reported anti-D, 33% IVIG, 20% prednisone, and 2% other regimens. Only 34% of physicians would always or usually hospitalize such a patient. Hospitalization was more likely if a physician responded that he or she would always or usually use drug therapy. Physicians who saw more ITP patients were more likely to self-report sometimes or rarely/never prescribing drug therapy. Self-reported initial management of ITP by ASPH/O members in 2001 is similar to 1997 regarding the percentage of pediatric hematologists who would not use drug therapy. Among physicians who would use drug treatment, there was an increased use of anti-D and decreased use of IVIG and prednisone. This information provides the basis for designing a randomized clinical trial to compare the effect of different management strategies on the outcomes of bleeding symptoms, side effects of therapy, costs, and quality of life.
This paper references
10.1136/adc.67.8.1056
Guidelines for management of idiopathic thrombocytopenic purpura. The British Paediatric Haematology Group.
O. Eden (1992)
10.1016/S0022-3476(05)80400-7
A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura.
V. Blanchette (1993)
10.1182/BLOOD.V88.1.3.BLOODJOURNAL8813
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
J. George (1996)
Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the
J N George (1996)
Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3–40
JN George (1996)
British Paediatric Haematology Group. Guidelines for management of idiopathic thrombocytopenic purpura
OB Eden (1997)
10.1016/S0022-3476(99)70361-6
Immune thrombocytopenic purpura: why treat?
D. Nugent (1999)
10.1111/j.1365-2141.1999.01409.x
Management of childhood idiopathic thrombocytopenic purpura
J. Lilleyman (1999)
10.1097/00043426-200001000-00011
Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists.
S. Vesely (2000)
10.1097/00008480-200002000-00002
Idiopathic thrombocytopenic purpura: beyond consensus.
D. Medeiros (2000)
10.1067/MPD.2000.111164
Initial management of immune thrombocytopenic purpura in children: is supportive counseling without therapeutic intervention sufficient?
J. George (2000)
10.1067/MPD.2000.110123
The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment.
R. Dickerhoff (2000)
National audit of the management of childhood idiopathic thrombocytopenic purpura against UK guidelines : closing the loop : education and reaudit demonstrate a change in practice
Bolton-Maggs PHB (2001)
National audit of the management of childhood idiopathic thrombocytopenic purpura against UK guidelines: closing the loop: education and re-audit demonstrate a change in practice. Blood 2001;98:58b
PHB Bolton-Maggs (2001)



This paper is referenced by
10.1007/978-3-030-48446-0_21
Immune Thrombocytopenia in Adolescents
A. Griffith (2020)
10.1016/J.THROMRES.2019.08.002
Results of a multinational survey of diagnostic and management practices of thromboembolic pulmonary embolism in children.
M. Rajpurkar (2019)
10.1002/ajh.25110
Physician decision making in selection of second‐line treatments in immune thrombocytopenia in children
R. Grace (2018)
10.1097/MPH.0000000000001247
A Quality Improvement Bundle to Improve Informed Choice for Children With Typical, Newly Diagnosed Immune Thrombocytopenia
C. Beck (2018)
10.1016/j.thromres.2017.05.010
Epidemiology and management of primary immune thrombocytopenia: A nationwide population-based study in Korea.
J. Lee (2017)
10.3109/09537104.2016.1143923
Hospitalizations in pediatric patients with immune thrombocytopenia in the United States
M. Tarantino (2016)
10.1097/MAJ.0b013e31827f4dd1
Management of Primary Immune Thrombocytopenia, 2012: A Survey of Oklahoma Hematologists-Oncologists
K. Lu (2014)
10.1016/j.bmc.2014.03.016
Structure-activity relationships of pyrazole derivatives as potential therapeutics for immune thrombocytopenias.
Meena K. Purohit (2014)
10.1001/jamapediatrics.2014.2214
Influence of the American Society of Hematology guidelines on the management of newly diagnosed childhood immune thrombocytopenia.
Corinna L Schultz (2014)
10.1097/MPH.0000000000000120
Shared Decision Making in the Management of Children With Newly Diagnosed Immune Thrombocytopenia
C. Beck (2014)
10.1016/B978-1-4557-2296-9.00009-9
9 – Primary Immune Thrombocytopenia
James N George (2013)
thrombocytopenic purpura Severe hemorrhage in children with newly diagnosed immune
J. Neufeld (2013)
10.1097/MBC.0b013e32835e5337
A comparison of intravenous immunoglobulin (2 g/kg totally) and single doses of anti-D immunoglobulin at 50 &mgr;g/kg, 75 &mgr;g/kg in newly diagnosed children with idiopathic thrombocytopenic purpura: Ankara hospital experience
Bulent Alioglu (2013)
10.1002/pbc.24344
Bleeding severity as an important outcome in childhood immune thrombocytopenia
Adolfo Flores (2013)
10.1097/MPH.0b013e31820e2aa5
Standard-dose Intravenous Anti-D Immunoglobulin Versus Intravenous Immunoglobulin in the Treatment of Newly Diagnosed Childhood Primary Immune Thrombocytopenia
Andromachi Papagianni (2011)
10.1177/0272989X11400417
Decision Modeling of Disagreements
H. Lehmann (2011)
10.1111/j.1365-2141.2009.08057.x
Comparison of intravenous immune globulin and high dose anti‐D immune globulin as initial therapy for childhood immune thrombocytopenic purpura
I. Kane (2010)
10.1002/pbc.21934
Controversies in the diagnosis and management of childhood acute immune thrombocytopenic purpura
G. Segel (2009)
10.1002/pbc.22146
Varied opinions on thrombolysis for venous thromboembolism in infants and children: Findings from a survey of pediatric hematology–oncology specialists
D. Yee (2009)
10.1182/blood-2008-03-138487
Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura.
C. Neunert (2008)
10.1007/s12098-008-0243-y
Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura
E. Shahgholi (2008)
10.1016/J.ARCPED.2008.06.007
Purpura thrombocytopénique auto-immun : à propos d’une cohorte prospective de 147 enfants pris en charge dans le réseau d’hématologie pédiatrique des régions PACA et Corse (RHémaP)
M. Meignen (2008)
10.1159/000112837
Management of Acute Childhood Idiopathic Thrombocytopenic Purpura according to AIEOP Consensus Guidelines: Assessment of Italian Experience
G. D. Del Vecchio (2008)
10.1097/MPH.0b013e31817541ba
A Single Dose of Anti-D Immunoglobulin Raises Platelet Count as Efficiently as Intravenous Immunoglobulin in Newly Diagnosed Immune Thrombocytopenic Purpura in Korean Children
D. W. Son (2008)
10.1097/MOH.0b013e3282ab98df
Update on the management of immune thrombocytopenic purpura in children
M. Tarantino (2007)
10.1016/J.ARCPED.2006.12.005
La prise en charge du purpura thrombopénique idiopathique en phase initiale : enquête auprès des membres de la Société française d'hématologie et d'immunologie pédiatrique (SHIP)
P. Lutz (2007)
10.1002/pbc.20894
What is the “cost” of acute ITP?
G. Buchanan (2007)
Vincristine Effect for the Treatment of Idiopathic Thrombocytopenic Purpura in Childhood
C. H. Hong (2007)
10.1016/B978-141602401-9.10009-4
Chapter 9 – Immune Thrombocytopenic Purpura
J. George (2007)
10.1097/MOH.0b013e3282ab98f2
Diagnosis of immune thrombocytopenic purpura in children
A. Geddis (2007)
10.1097/MPH.0b013e3180320b36
Chronic Immune Thrombocytopenic Purpura in Children: A Survey of the Canadian Experience
M. Belletrutti (2007)
10.1002/pbc.20830
A cost‐utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP)
Sarah H. O'Brien (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar